Literature DB >> 17252527

First-trimester treatment of fetal anemia secondary to parvovirus B19 infection.

A Kempe1, B Rösing, C Berg, D Kamil, A Heep, U Gembruch, A Geipel.   

Abstract

Here we report two cases of first-trimester parvovirus B19 (PV-B19) infection that were successfully treated by intrauterine blood transfusion into the umbilical vein. At 13 weeks' gestation both fetuses presented with increased nuchal translucency (NT) and cardiomegaly. In both cases pulsed Doppler ultrasound examination of the fetal middle cerebral artery (MCA) revealed increased peak systolic velocity (PSV), which led to a suspicion of fetal anemia. Maternal PV infection was confirmed by a positive polymerase chain reaction result. Each fetus received a 3-mL intravenous transfusion of packed red blood cells into the umbilical vein, using a 25-G spinal needle. Follow-up ultrasound and Doppler examination demonstrated fetal well-being, decline of the MCA-PSV and resolution of the NT. Case 1 was readmitted at 25 weeks' gestation with severe hydrops fetalis, and both mother and fetus still tested positive for PV-B19 DNA. Three more intrauterine blood transfusions were performed and the fetal hydrops resolved. In Case 2 no additional transfusions were needed. Both babies had a good neonatal outcome and uneventful follow-up. Our findings demonstrate that the MCA-PSV is helpful in establishing the diagnosis of first-trimester fetal anemia. Intravasal transfusion can be attempted as early as the first trimester. Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17252527     DOI: 10.1002/uog.3925

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  1 in total

1.  Intrauterine transfusion in 103 fetuses with severe anemia caused by parvovirus infection. A multicenter retrospective study.

Authors:  Philipp Kosian; Astrid Hellmund; Annegret Geipel; Rainer Bald; Otilia-Maria Geist; Paul Böckenhoff; Jorge Jimenez-Cruz; Maria Deja; Brigitte Strizek; Christoph Berg; Ulrich Gembruch
Journal:  Arch Gynecol Obstet       Date:  2022-08-02       Impact factor: 2.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.